Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
13.6m
Last Price
$0.5103
52-Week Range
$0.54 - $3.85
02/02/2026 09:00 PM EST